Table 8

Studies of cigarette smoking and breast cancer risk according to NAT2 genotypes

First author, study yearStudy designNo. of cases/controls (or no. in cohort)ComparisonPremenopausalPostmenopausal
NAT2 rapidNAT2 slowNAT2 rapidNAT2 slow
OR (95% CI)aOR (95% CI)OR (95% CI)OR (95% CI)
Chang-Claude, 2002 (110)Case-controlb422/88720+ years’ duration active vs. never1.2 (0.6–2.4)1.8 (1.1–3.2)c
21+ years’ duration passive vs. never2.9 (1.1–7.6)1.0 (0.5–2.0)c
Morabia, 2000 (69)Case-controlb177/170Current 20+ cpd vs. never exposed5.3 (1.4–20.5)1.6 (0.7–6.9)c
Millikan, 1998 (66)Case-controlb498/473>20 years’ duration vs. never1.7 (0.7–4.2)1.3 (0.6–2.8)1.8 (1.0–3.2)1.9 (0.7–5.5)
Hunter, 1997 (58)Cohortd466/46630+ pack-years vs. never0.8 (0.5–1.5)1.4 (0.8–2.3)e
Ambrosone, 1996 (46)Case-controlb304/327>18.25 pack-years vs. never2.1 (0.5–7.9)1.2 (0.4–3.8)0.9 (0.4–2.1)2.8 (1.4–5.5)
  • a OR, odds ratio; CI, confidence interval.

  • b A population-based case-control study.

  • c The results shown were based on both premenopausal and postmenopausal women; cpd, cigarettes per day.

  • d A nested case-control study.

  • e The results shown were based on both premenopausal and postmenopausal women. There was no association among premenopausal women of either slow or rapid acetylation genotypes.